Outcome of the board meeting

Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹174.10

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-2.1% vs market

Pharmaceuticals & Biotechnology peers, median of 162sector · industry level+0.1%-1.6% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.6-2.1+0.1-1.6

Next day

-3.4-0.2-3.2-0.7-2.8

-5.4-0.4-5.0-1.2-4.2

-7.2-0.7-6.5-1.1-6.2

-9.1-2.2-6.9-2.0-7.1

-10.9-2.8-8.1-3.2-7.7

-14.4-1.4-13.0-2.2-12.2

15d

-39.3-7.0-32.3-4.9-34.4

-51.2-6.1-45.1-5.5-45.7

-56.9-9.2-47.7-7.8-49.1

-62.3-6.8-55.4-9.6-52.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved unaudited financial results for Q2 and H1 FY26 ended September 30, 2025. The company swung to a net loss of ₹6.47 lakhs in Q2 FY26 and ₹18.28 lakhs in H1 FY26, compared with profits of ₹364.91 lakhs and ₹355.34 lakhs in the year-ago periods. Reported total income remained at ₹366.72 lakhs across periods, but the current-period losses exactly match total expenses, indicating that the income line is largely non-operating/legacy and core operations are not generating revenue. Total expenses rose to ₹18.28 lakhs in H1 FY26 from ₹11.38 lakhs a year ago. The balance sheet shows negative other equity of ₹(465.02) lakhs against share capital of ₹1,300 lakhs, meaning accumulated losses have eroded over a third of net worth. The statutory auditor, M.N. Rao & Associates LLP, issued a clean (unmodified) limited review report.

Likely market impact

The sharp reversal from profit to loss suggests prior-year earnings were driven by one-time, non-recurring items rather than sustainable operations. Combined with deeply negative reserves, this is a negative signal for shareholders and indicates weak core earning capacity.